Emerald Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-317,096
| Closed | -$32.3M | – | 247 |
|
|
2023
Q2 | $32.3M | Buy |
317,096
+2,475
| +0.8% | +$234K | 1.41% | 11 |
|
|
2023
Q1 | $28.6M | Sell |
314,621
-365,151
| -54% | -$21.4M | 1.37% | 13 |
|
|
2022
Q4 | $25.8M | Buy |
679,772
+141,520
| +26% | +$4.87M | 1.25% | 27 |
|
|
2022
Q3 | $13.5M | Buy |
538,252
+252,071
| +88% | +$6.99M | 0.7% | 65 |
|
|
2022
Q2 | $8.7M | Buy |
286,181
+15,335
| +6% | +$457K | 0.45% | 85 |
|
|
2022
Q1 | $8.87M | Buy |
270,846
+91,974
| +51% | +$2.73M | 0.34% | 99 |
|
|
2021
Q4 | $4.72M | Sell |
178,872
-97,283
| -35% | -$7.53M | 0.17% | 113 |
|
|
2021
Q3 | $27.8M | Buy |
276,155
+29,712
| +12% | +$3.48M | 1.01% | 35 |
|
|
2021
Q2 | $34.9M | Sell |
246,443
-15,024
| -6% | -$1.7M | 1.27% | 21 |
|
|
2021
Q1 | $26.1M | Buy |
+261,467
| New | +$30.5M | 0.94% | 31 |
|
|
2020
Q3 | – | Sell |
-63,472
| Closed | -$9.9M | – | 365 |
|
|
2020
Q2 | $9.9M | Sell |
63,472
-51,064
| -45% | -$7.76M | 0.43% | 87 |
|
|
2020
Q1 | $16.5M | Buy |
114,536
+12,427
| +12% | +$2.4M | 0.96% | 35 |
|
|
2019
Q4 | $20.9M | Sell |
102,109
-180,709
| -64% | -$33M | 0.88% | 41 |
|
|
2019
Q3 | $22.7M | Sell |
282,818
-104,551
| -27% | -$8.87M | 1.06% | 32 |
|
|
2019
Q2 | $36.5M | Sell |
387,369
-4,720
| -1% | -$408K | 1.47% | 18 |
|
|
2019
Q1 | $33.5M | Sell |
392,089
-78,342
| -17% | -$6.5M | 1.36% | 20 |
|
|
2018
Q4 | $26.4M | Sell |
470,431
-2,844
| -0.6% | -$174K | 1.3% | 20 |
|
|
2018
Q3 | $38.7M | Sell |
473,275
-72,245
| -13% | -$5.09M | 1.42% | 11 |
|
|
2018
Q2 | $19.1M | Buy |
545,520
+51,767
| +10% | +$1.58M | 0.72% | 61 |
|
|
2018
Q1 | $10.1M | Sell |
493,753
-67,983
| -12% | -$1.75M | 0.41% | 102 |
|
|
2017
Q4 | $15.9M | Sell |
561,736
-7,680
| -1% | -$214K | 0.61% | 65 |
|
|
2017
Q3 | $17.7M | Buy |
569,416
+162,990
| +40% | +$4.9M | 0.72% | 59 |
|
|
2017
Q2 | $12.9M | Buy |
406,426
+36,227
| +10% | +$891K | 0.54% | 78 |
|
|
2017
Q1 | $8.38M | Buy |
370,199
+43,052
| +13% | +$1.06M | 0.34% | 103 |
|
|
2016
Q4 | $7.14M | Buy |
327,147
+86,269
| +36% | +$2.18M | 0.3% | 104 |
|
|
2016
Q3 | $6.35M | Buy |
240,878
+73,268
| +44% | +$1.45M | 0.28% | 122 |
|
|
2016
Q2 | $3.31M | Buy |
+167,610
| New | +$3.26M | 0.16% | 160 |
|
Other funds holding RETA
Emerald Advisers's RETA Position: Q3 2023 in Review
Emerald Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 317,096 shares — an estimated $32.3M sold.
Emerald Advisers first reported a position in RETA in Q2 2016 and held it in 27 quarters. The position peaked at $38.7M in Q3 2018. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Emerald Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Emerald Advisers sold 317,096 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $32.3M.
- Emerald Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 27 quarters.
- Emerald Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $38.7M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Emerald Advisers's 13F filing for Q3 2023, filed 26 Oct 2023.